JP2014513953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014513953A5 JP2014513953A5 JP2014506589A JP2014506589A JP2014513953A5 JP 2014513953 A5 JP2014513953 A5 JP 2014513953A5 JP 2014506589 A JP2014506589 A JP 2014506589A JP 2014506589 A JP2014506589 A JP 2014506589A JP 2014513953 A5 JP2014513953 A5 JP 2014513953A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- bms3h
- antibody polypeptide
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 28
- 229920001184 polypeptide Polymers 0.000 claims 27
- 102000004196 processed proteins & peptides Human genes 0.000 claims 27
- 150000001413 amino acids Chemical class 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 11
- 230000004927 fusion Effects 0.000 claims 3
- 208000026278 immune system disease Diseases 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 101150013553 CD40 gene Proteins 0.000 claims 2
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000007815 allergy Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000026872 Addison Disease Diseases 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000000104 Arthus reaction Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003645 Atopy Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000022555 Genital disease Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims 1
- 208000001204 Hashimoto Disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 208000007466 Male Infertility Diseases 0.000 claims 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 241000721454 Pemphigus Species 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 206010053614 Type III immune complex mediated reaction Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000003068 rheumatic fever Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161477904P | 2011-04-21 | 2011-04-21 | |
| US61/477,904 | 2011-04-21 | ||
| PCT/US2012/034519 WO2012145673A1 (en) | 2011-04-21 | 2012-04-20 | Antibody polypeptides that antagonize cd40 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000493A Division JP2017099391A (ja) | 2011-04-21 | 2017-01-05 | Ｃｄ４０を拮抗する抗体ポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014513953A JP2014513953A (ja) | 2014-06-19 |
| JP2014513953A5 true JP2014513953A5 (enExample) | 2015-04-23 |
| JP6114256B2 JP6114256B2 (ja) | 2017-04-12 |
Family
ID=46000407
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014506589A Expired - Fee Related JP6114256B2 (ja) | 2011-04-21 | 2012-04-20 | Ｃｄ４０を拮抗する抗体ポリペプチド |
| JP2017000493A Pending JP2017099391A (ja) | 2011-04-21 | 2017-01-05 | Ｃｄ４０を拮抗する抗体ポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000493A Pending JP2017099391A (ja) | 2011-04-21 | 2017-01-05 | Ｃｄ４０を拮抗する抗体ポリペプチド |
Country Status (35)
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE065915T2 (hu) | 2011-03-11 | 2024-06-28 | Beth Israel Deaconess Medical Ct Inc | Anti-CD40 antitestek és alkalmazásaik |
| US9475879B2 (en) | 2011-04-21 | 2016-10-25 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
| CN103635488B (zh) | 2011-04-29 | 2016-12-14 | 埃派斯进有限公司 | 抗-cd40抗体及其使用方法 |
| SMT202000091T1 (it) | 2011-10-13 | 2020-05-08 | Bristol Myers Squibb Co | Polipeptidi anticorpali che antagonizzano cd40l |
| EP2914627B1 (en) | 2012-10-30 | 2021-04-07 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| US10435475B2 (en) | 2014-03-07 | 2019-10-08 | Bristol-Myers Squibb Company | Method of using antibody polypeptides that antagonize CD40 to treat IBD |
| AU2015360502A1 (en) | 2014-12-10 | 2017-06-29 | Regents Of The University Of Minnesota | Genetically modified cells, tissues, and organs for treating disease |
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| MA41459A (fr) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | Anticorps anti-cd40l et méthodes pour traiter des maladies ou des troubles liés aux cd40l |
| JP2018518474A (ja) * | 2015-05-27 | 2018-07-12 | ラ・ホヤ・バイオロジクス・インコーポレイテッド | グリピカン−３に対する抗体並びにがん診断及び治療におけるそれらの使用 |
| UY36692A (es) | 2015-05-29 | 2016-12-30 | Abbvie Inc | Anticuerpos anti-cd40 y usos de los mismos |
| EP3307322B1 (en) | 2015-09-04 | 2021-02-17 | Primatope Therapeutics Inc. | Humanized anti-cd40 antibodies and uses thereof |
| US20190086405A1 (en) | 2016-03-16 | 2019-03-21 | Bristol-Myers Squibb Company | Methods of diagnosing and treating lupus |
| BR112018076260A2 (pt) | 2016-06-20 | 2019-03-26 | Kymab Limited | anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina |
| KR102019033B1 (ko) | 2016-11-11 | 2019-09-06 | 다이노나(주) | Cd40에 특이적으로 결합하는 항체 및 그의 용도 |
| WO2018115003A2 (en) | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
| EP3600421A4 (en) * | 2017-03-23 | 2021-01-06 | The Trustees of The University of Pennsylvania | ANTI-C5A ANTIBODIES AND USES OF THEM |
| EP3630843A2 (en) | 2017-05-24 | 2020-04-08 | ALS Therapy Development Institute | Therapeutic anti-cd40 ligand antibodies |
| CN110637035A (zh) | 2017-05-25 | 2019-12-31 | 百时美施贵宝公司 | 经修饰的IgG1 Fc结构域与抗-CD40域抗体的融合 |
| KR102713355B1 (ko) | 2017-05-25 | 2024-10-02 | 브리스톨-마이어스 스큅 컴퍼니 | 길항작용 cd40 모노클로날 항체 및 그의 용도 |
| BR112019018759A2 (pt) | 2017-05-30 | 2020-05-05 | Bristol-Myers Squibb Company | composições compreendendo uma combinação de um anticorpo anti-lag-3, um inibidor da via pd-1, e um agente imunoterápico |
| CN110267989B (zh) | 2017-06-01 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 抗cd40抗体、其抗原结合片段及其医药用途 |
| KR20210035805A (ko) | 2018-06-15 | 2021-04-01 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가 |
| AR117091A1 (es) * | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
| JP2022509156A (ja) | 2018-11-30 | 2022-01-20 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 |
| CN112839961B (zh) | 2018-11-30 | 2023-04-04 | 江苏恒瑞医药股份有限公司 | 一种cd40抗体药物组合物及其用途 |
| SG11202108141VA (en) * | 2019-02-01 | 2021-08-30 | Lava Therapeutics B V | Novel cd40-binding antibodies |
| MA55805A (fr) | 2019-05-03 | 2022-03-09 | Flagship Pioneering Innovations V Inc | Métodes de modulation de l'activité immunitaire |
| US20210032356A1 (en) * | 2019-08-02 | 2021-02-04 | Eastern Virginia Medical School | Method for treating seizures |
| US20230114107A1 (en) | 2019-12-17 | 2023-04-13 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| US11926672B2 (en) | 2019-12-20 | 2024-03-12 | Amgen Inc. | Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| US11862306B1 (en) | 2020-02-07 | 2024-01-02 | Cvs Pharmacy, Inc. | Customer health activity based system for secure communication and presentation of health information |
| WO2021216956A1 (en) * | 2020-04-23 | 2021-10-28 | Alpha Beta Holdings, Llc | Compositions and methods for treating cancer |
| WO2021236546A1 (en) | 2020-05-18 | 2021-11-25 | Bristol-Myers Squibb Company | Antibody variants with improved pharmacokinetic properties |
| US20230355804A1 (en) | 2020-06-29 | 2023-11-09 | Flagship Pioneering Innovations V, Inc. | Viruses engineered to promote thanotransmission and their use in treating cancer |
| CA3214085A1 (en) | 2021-03-31 | 2022-10-06 | Darby Rye Schmidt | Thanotransmission polypeptides and their use in treating cancer |
| KR20240026507A (ko) | 2021-06-29 | 2024-02-28 | 플래그쉽 파이어니어링 이노베이션스 브이, 인크. | 타노트랜스미션을 촉진시키도록 엔지니어링된 면역 세포 및 이의 용도 |
| US12234294B2 (en) | 2021-11-05 | 2025-02-25 | Kiniksa Pharmaceuticals, Gmbh | Pharmaceutical composition of a humanized anti-CD40 antibody |
| CN114149508B (zh) * | 2021-11-25 | 2023-04-28 | 苏州普乐康医药科技有限公司 | 一种结合cd40l的融合蛋白及其应用 |
| AU2023230110A1 (en) | 2022-03-08 | 2024-10-24 | Alentis Therapeutics Ag | Use of anti-claudin-1 antibodies to increase t cell availability |
| CN116023495B (zh) * | 2022-09-05 | 2023-10-03 | 上海百英生物科技股份有限公司 | 一种抗cd40纳米抗体及其制备方法与应用 |
| WO2024077191A1 (en) | 2022-10-05 | 2024-04-11 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| KR20250057233A (ko) | 2023-10-20 | 2025-04-29 | 한상진 | 이동식 무선 자동 제습기 |
| WO2025129007A1 (en) * | 2023-12-15 | 2025-06-19 | Werewool Inc. | Soy alginate fibers |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
| US20250277048A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | The use of cd40 inhibitors for inhibiting an immune response and enabling immunogen administration and re-administration |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5182368A (en) | 1986-06-13 | 1993-01-26 | Ledbetter Jeffrey A | Ligands and methods for augmenting B-cell proliferation |
| US5247069A (en) | 1986-06-13 | 1993-09-21 | Oncogen | Ligands and methods for augmenting B-cell proliferation |
| US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
| CA2089229C (en) | 1992-02-14 | 2010-04-13 | Alejandro A. Aruffo | Cd40cr receptor and ligands therefor |
| US5397703A (en) | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
| DE69433820T2 (de) | 1993-12-23 | 2005-06-23 | Immunex Corp., Seattle | Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten |
| JP4751493B2 (ja) | 1996-03-20 | 2011-08-17 | ブリストル−マイヤーズ スクイッブ カンパニー | Ｇｐ３９／ｃｄ４０およびｃｔｌａ４／ｃｄ２８／ｂ７経路のブロックによって免疫反応を阻止する方法およびそれに使用する組成物 |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6051228A (en) | 1998-02-19 | 2000-04-18 | Bristol-Myers Squibb Co. | Antibodies against human CD40 |
| WO2002028481A2 (en) * | 2000-10-02 | 2002-04-11 | Chiron Corporation | Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| RS53073B (sr) * | 2003-11-04 | 2014-04-30 | Novartis Vaccines And Diagnostics Inc. | Upotreba antagonističkih anti-cd40 monoklonska antitela |
| RU2377254C2 (ru) * | 2003-12-25 | 2009-12-27 | Кирин Фарма Кабусики Кайся | Мутанты анти-cd40 антитела |
| PT1737962E (pt) | 2004-03-24 | 2010-12-03 | Domantis Ltd | Sequência líder universal gas1 |
| KR20070026522A (ko) | 2004-04-27 | 2007-03-08 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 길항제 항-ｃｄ40 모노클론 항체 및 이들의 사용 방법 |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| CN101061140B (zh) * | 2004-09-17 | 2015-07-01 | 多曼蒂斯有限公司 | 单价结合cd40l的组合物和应用方法 |
| AR053579A1 (es) | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
| US20110129412A1 (en) * | 2005-06-02 | 2011-06-02 | Astrazeneca Ab | Antibodies Directed to CD20 and Uses Thereof |
| AR057253A1 (es) * | 2005-12-16 | 2007-11-21 | Genentech Inc | Anticuerpos anti-ox40l y metodos que los utilizan |
| AU2007209202A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Ligands that bind IL-4 and/or IL-13 |
| GEP20125628B (en) | 2006-04-21 | 2012-09-10 | Novartis Ag | Pharmaceutical compositions containing antagonist anti-cd40 antibody |
| EP1854810A1 (en) | 2006-05-09 | 2007-11-14 | PanGenetics B.V. | Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody |
| GB0724331D0 (en) | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| BRPI0911442A2 (pt) * | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
| CN104398471A (zh) * | 2008-11-28 | 2015-03-11 | Abbvie公司 | 稳定的抗体组合物和用于稳定其的方法 |
| RS60612B1 (sr) | 2010-03-31 | 2020-08-31 | Boehringer Ingelheim Int | Anti-cd40 antitela |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| US9475879B2 (en) | 2011-04-21 | 2016-10-25 | Bristol-Myers Squibb Company | Antibody polypeptides that antagonize CD40 |
-
2012
- 2012-04-20 US US14/112,049 patent/US9475879B2/en active Active
- 2012-04-20 BR BR112013026828A patent/BR112013026828A2/pt not_active Application Discontinuation
- 2012-04-20 PT PT127170272T patent/PT2699601T/pt unknown
- 2012-04-20 CN CN201280030683.4A patent/CN103842382B/zh not_active Expired - Fee Related
- 2012-04-20 MA MA36322A patent/MA35035B1/fr unknown
- 2012-04-20 TW TW105121984A patent/TWI598363B/zh not_active IP Right Cessation
- 2012-04-20 LT LTEP12717027.2T patent/LT2699601T/lt unknown
- 2012-04-20 EA EA201391564A patent/EA030851B1/ru not_active IP Right Cessation
- 2012-04-20 PE PE2013002381A patent/PE20141188A1/es active IP Right Grant
- 2012-04-20 CA CA2833743A patent/CA2833743A1/en not_active Abandoned
- 2012-04-20 SI SI201231203T patent/SI2699601T1/en unknown
- 2012-04-20 JP JP2014506589A patent/JP6114256B2/ja not_active Expired - Fee Related
- 2012-04-20 CN CN201710070840.9A patent/CN106977604A/zh active Pending
- 2012-04-20 HR HRP20180571TT patent/HRP20180571T1/hr unknown
- 2012-04-20 NO NO12717027A patent/NO2699601T3/no unknown
- 2012-04-20 PL PL12717027T patent/PL2699601T3/pl unknown
- 2012-04-20 ME MEP-2018-94A patent/ME03071B/me unknown
- 2012-04-20 HU HUE12717027A patent/HUE038848T2/hu unknown
- 2012-04-20 MX MX2013011966A patent/MX354243B/es active IP Right Grant
- 2012-04-20 KR KR1020137030492A patent/KR101734614B1/ko not_active Expired - Fee Related
- 2012-04-20 AU AU2012245309A patent/AU2012245309C1/en not_active Ceased
- 2012-04-20 RS RS20180346A patent/RS57087B1/sr unknown
- 2012-04-20 KR KR1020177011260A patent/KR101905346B1/ko not_active Expired - Fee Related
- 2012-04-20 SG SG2013078183A patent/SG194561A1/en unknown
- 2012-04-20 ES ES12717027.2T patent/ES2664619T3/es active Active
- 2012-04-20 SM SM20180228T patent/SMT201800228T1/it unknown
- 2012-04-20 DK DK12717027.2T patent/DK2699601T3/en active
- 2012-04-20 MY MYPI2013003839A patent/MY165090A/en unknown
- 2012-04-20 EP EP18151812.7A patent/EP3372616A1/en not_active Withdrawn
- 2012-04-20 AR ARP120101368A patent/AR086360A1/es unknown
- 2012-04-20 EP EP12717027.2A patent/EP2699601B1/en active Active
- 2012-04-20 WO PCT/US2012/034519 patent/WO2012145673A1/en not_active Ceased
- 2012-04-20 TW TW101114258A patent/TW201245225A/zh unknown
-
2013
- 2013-09-27 PH PH12013502013A patent/PH12013502013B1/en unknown
- 2013-10-03 IL IL228720A patent/IL228720B/en active IP Right Grant
- 2013-10-11 TN TNP2013000417A patent/TN2013000417A1/fr unknown
- 2013-10-21 CL CL2013003043A patent/CL2013003043A1/es unknown
- 2013-11-05 CO CO13261140A patent/CO6801649A2/es active IP Right Grant
-
2016
- 2016-04-27 AU AU2016202672A patent/AU2016202672B2/en not_active Ceased
- 2016-09-08 US US15/259,828 patent/US10544228B2/en active Active
-
2017
- 2017-01-05 JP JP2017000493A patent/JP2017099391A/ja active Pending
-
2018
- 2018-04-16 CY CY181100398T patent/CY1120637T1/el unknown
-
2019
- 2019-12-20 US US16/723,047 patent/US11136406B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014513953A5 (enExample) | ||
| JP2014530611A5 (enExample) | ||
| JP2017099391A5 (enExample) | ||
| AU2016351710B2 (en) | Improved serum albumin-binding immunoglobulin variable domains | |
| JP2020521458A5 (enExample) | ||
| AU2016357460B2 (en) | Improved serum albumin binders | |
| KR101836217B1 (ko) | Ｉｌ-１７ａ 길항제 | |
| CN108473563B (zh) | 改进的tnf结合剂 | |
| HRP20200230T1 (hr) | Polipeptidi antitijela koji antagoniziraju cd40l | |
| CN104774266B (zh) | 白介素-13结合蛋白 | |
| WO2010055366A4 (en) | Anti-human il-21 monoclonal antibodies | |
| JP2017501711A5 (enExample) | ||
| CN106573053B (zh) | 干扰素α和ω抗体拮抗剂 | |
| RU2017134274A (ru) | Связывающие tslp белки | |
| JP2014503209A5 (enExample) | ||
| TW201031421A (en) | IL-1 binding proteins | |
| TW200911831A (en) | Polypeptides, antibody variable domains & antagonists | |
| JP2018537421A5 (enExample) | ||
| WO2017215524A1 (zh) | 抗人白细胞介素-17a单克隆抗体、其制备方法和应用 | |
| JP2012500020A5 (enExample) | ||
| WO2015137843A1 (ru) | Анти-il-17-антитела, способ их получения и способ применения | |
| CN104105704A (zh) | Il4/il13结合重复蛋白及用途 | |
| JP2019504822A5 (enExample) | ||
| CN104271598A (zh) | 针对IgE的免疫球蛋白单可变结构域 | |
| AU2016369307A1 (en) | Multi-specific antibody molecules having specificity for TNF-alpha, IL-17A and IL-17F |